絞り込み

16404

広告

目標上積みの「タラノア対話」合意 (毎日新聞)

[PR] 温室ガス削減 「パリ協定」控え18年の1年間かけ実施へ 【ボン五十嵐和大】ドイツのボンで開催中の国連気候変動枠組み条約第23回締約国会議(COP23)...

  1. ドイツの温暖化会議で決議採択 - 福井新...
  2. 国内初の種類 恐竜の卵の化石を展示 山口...
  3. 温暖化、COP23大筋合意 先進国の削減...
  4. 本人望めば蘇生中止 消防庁委託研究班提言...

ニュース一覧

Therapeutic approach for relapsed/refractory multiple myeloma: the logic and practice.

著者 Kuroda J
Rinsho Ketsueki.2017 ; 58(10):2058-2066.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (30view , 0users)

Full Text Sources

The long-term outcome of multiple myeloma (MM) has been greatly improved by the advent of new agents such as proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs), despite the disease remaining mostly incurable. Treatment design is the critical determinant for the survival period and for the quality and way of life in patients with relapsed/refractory MM (RRMM). Recently, the choice of therapeutic options for RRMM has been expanded by the introduction of second generation PIs such as carfilzomib and ixazomib, and therapeutic monoclonal antibodies such as elotuzumab and daratumumab. In the choice of treatment strategies for RRMM, including stem cell transplantation, the decision should be based on an understanding of the characteristic clinical effects of each drug and the evaluation of the cytogenetic/molecular profile, myeloma-defining events, complications, and prior MM treatment history in individual patients.
PMID: 28978849 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード